Literature DB >> 2998117

The complete sequence of bluetongue virus serotype 10 segment 3 and its predicted VP3 polypeptide compared with those of BTV serotype 17.

H Ghiasi, M A Purdy, P Roy.   

Abstract

The complete sequence of the large RNA segment 3 (L3) of bluetongue virus serotype 10 (BTV-10) has been determined from DNA copies of the viral RNA cloned in the E. coli plasmid pBR322. The L3 viral RNA is 2772 nucleotides long with a single open reading frame of 2706 nucleotides. The L3 predicted primary gene product (VP3) is 103 342 daltons and has a net charge at neutral pH of -5. The sequence of the L3 RNA species differs by 126 point mutations from that of BTV-17 (i.e., 95.5% homology; see M. Purdy, J. Petre and P. Roy, J. Virol. 51, 754-759, 1984). The predicted L3 primary gene products of the two viruses differ by 9 amino acids. These differences correspond to 9 point mutations and represent 0.15% of the sites where nucleotide substitution could cause an amino acid change. By contrast, another 114 point mutations in the genome correspond to 6.5% of the available sites where nucleotide substitutions could be silent (i.e., where a nucleotide substitution may not cause an amino acid change). Three point mutations are in the 3' non-coding region of the RNA species. The quantitative differences between the coding and silent mutations are interpreted as representing the result of gene product conservation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2998117     DOI: 10.1016/0168-1702(85)90007-3

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  10 in total

1.  Herpes Simplex Virus 1 ICP22 Suppresses CD80 Expression by Murine Dendritic Cells.

Authors:  Harry Matundan; Homayon Ghiasi
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

2.  Nucleotide sequence of the VP4 core protein gene (M4 RNA) of US bluetongue virus serotype 10.

Authors:  Y D Yu; A Fukusho; P Roy
Journal:  Nucleic Acids Res       Date:  1987-09-11       Impact factor: 16.971

3.  Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV.

Authors:  T J French; P Roy
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

4.  Assembly and intracellular localization of the bluetongue virus core protein VP3.

Authors:  Alak Kanti Kar; Nao Iwatani; Polly Roy
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  Development of PCR-based tests for the identification of North American isolates of epizootic haemorrhagic disease virus.

Authors:  M J Harding; I Prud'homme; J Rola; G C Dulac
Journal:  Can J Vet Res       Date:  1996-01       Impact factor: 1.310

6.  Synthesis and characterization of chimeric particles between epizootic hemorrhagic disease virus and bluetongue virus: functional domains are conserved on the VP3 protein.

Authors:  H Le Blois; B Fayard; T Urakawa; P Roy
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

7.  Evidence for genetic relationship between RNA and DNA viruses from the sequence homology of a putative polymerase gene of bluetongue virus with that of vaccinia virus: conservation of RNA polymerase genes from diverse species.

Authors:  P Roy; A Fukusho; G D Ritter; D Lyon
Journal:  Nucleic Acids Res       Date:  1988-12-23       Impact factor: 16.971

8.  The use of recombinant DNA probes to group and type orbiviruses. A comparison of Australian and South African isolates.

Authors:  A R Gould
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

9.  Oncolytic bluetongue viruses: promise, progress, and perspectives.

Authors:  Joseph K-K Li
Journal:  Front Microbiol       Date:  2011-03-16       Impact factor: 5.640

10.  Evolution and phylogenetic analysis of full-length VP3 genes of Eastern Mediterranean bluetongue virus isolates.

Authors:  Kyriaki Nomikou; Chrysostomos I Dovas; Sushila Maan; Simon J Anthony; Alan R Samuel; Maria Papanastassopoulou; Narender S Maan; Olga Mangana; Peter P C Mertens
Journal:  PLoS One       Date:  2009-07-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.